Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Epstein

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumorsNan Zhang, Leslie A Khawli, Peisheng Hu, et al.
Cancer Research|December 18, 2003
Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletionJiali Li, Peisheng Hu, Leslie A Khawli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Combination B7-Fc fusion protein treatment and Treg cell depletion therapyAihong Liu, Peisheng Hu, Leslie A Khawli, et al.
Antibodies (Basel, Switzerland)|June 14, 2020
Principles of <i>N</i>-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional ConsiderationsSouad Boune, Peisheng Hu, Alan L Epstein, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT)Barbara H Biela, Leslie A Khawli, Peisheng Hu, et al.
Journal of Leukocyte Biology|October 4, 2003
Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin GLuciano Ottonello, Alan L Epstein, Marina Mancini, et al.
Hybridoma and Hybridomics|May 7, 2002
Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cellsLeslie A Khawli, Barbara H Biela, Peisheng Hu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor modelsMeg L Flanagan, Leslie A Khawli, Peisheng Hu, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 19, 2004
Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibodyLeslie A Khawli, Mian M Alauddin, Peisheng Hu, et al.
Hybridoma and Hybridomics|March 6, 2004
chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumorsJiali Li, Peisheng Hu, Leslie A Khawli, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumorsNan Zhang, Leslie A Khawli, Peisheng Hu, et al.
Cancer Research|December 18, 2003
Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletionJiali Li, Peisheng Hu, Leslie A Khawli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Combination B7-Fc fusion protein treatment and Treg cell depletion therapyAihong Liu, Peisheng Hu, Leslie A Khawli, et al.
Antibodies (Basel, Switzerland)|June 14, 2020
Principles of <i>N</i>-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional ConsiderationsSouad Boune, Peisheng Hu, Alan L Epstein, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT)Barbara H Biela, Leslie A Khawli, Peisheng Hu, et al.
Journal of Leukocyte Biology|October 4, 2003
Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin GLuciano Ottonello, Alan L Epstein, Marina Mancini, et al.
Hybridoma and Hybridomics|May 7, 2002
Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cellsLeslie A Khawli, Barbara H Biela, Peisheng Hu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor modelsMeg L Flanagan, Leslie A Khawli, Peisheng Hu, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 19, 2004
Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibodyLeslie A Khawli, Mian M Alauddin, Peisheng Hu, et al.
Hybridoma and Hybridomics|March 6, 2004
chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumorsJiali Li, Peisheng Hu, Leslie A Khawli, et al.
Pageof 10